J&J's Erleada study succeeds in early-stage prostate cancer, but questions remain

Johnson & ​Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage study

The study, which followed patients for over five ‌years, found that those ⁠who received ⁠the regimen were nine times more likely to have little to no detectable cancer in the prostate at the time of surgery compared…